Actively Recruiting

Phase 3
Age: 18Years - 45Years
FEMALE
NCT06111079

Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia

Led by FANG HE · Updated on 2024-07-03

1800

Participants Needed

1

Research Sites

60 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most international guidelines default until 36 weeks of gestation or delivery. China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence. According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable. If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.

CONDITIONS

Official Title

Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia

Who Can Participate

Age: 18Years - 45Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Pregnant women with a normal NT scan before 16 weeks of gestation
  • Have at least 1 high-risk factor or at least 2 moderate-risk factors for preeclampsia
  • Intend to receive prenatal care and deliver at the study hospital
  • Provide written informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Aspirin started after 16 weeks of pregnancy
  • Allergy or intolerance to aspirin
  • Taking less than 80% of prescribed aspirin
  • Miscarriage or pregnancy termination before randomization
  • Dropped out by not returning to hospital for delivery
  • Lost to follow-up during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

FANG HE

Guangzhou, Guangdong, China, 510150

Actively Recruiting

Loading map...

Research Team

F

Fang He, M.D

CONTACT

Q

Qingwen Nie, Master

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia | DecenTrialz